Similar articles for PMID: 20508803

Year	Number of Results
1997	1
1998	1
2002	1
2003	2
2004	2
2005	2
2006	4
2007	4
2008	3
2009	7
2010	3
2011	1
2012	1
2013	6
2014	7
2015	8
2016	11
2017	2
2018	5
2019	7
2020	7
2021	4
2022	1
2024	1

1

Real-World Data on: Attention Deficit Hyperactivity Disorder Medication Side Effects.

Cascade E, Kalali AH, Wigal SB. Cascade E, et al. Psychiatry (Edgmont). 2010 Apr;7(4):13-5. Psychiatry (Edgmont). 2010. PMID: 20508803 Free PMC article.

2

Real-World Data on SSRI Antidepressant Side Effects.

Cascade E, Kalali AH, Kennedy SH. Cascade E, et al. Psychiatry (Edgmont). 2009 Feb;6(2):16-8. Psychiatry (Edgmont). 2009. PMID: 19724743 Free PMC article.

3

Attention-deficit hyperactivity disorder: recent advances in paediatric pharmacotherapy.

May DE, Kratochvil CJ. May DE, et al. Drugs. 2010;70(1):15-40. doi: 10.2165/11530540-000000000-00000. Drugs. 2010. PMID: 20030423

4

Priapism associated with the use of stimulant medications and atomoxetine for attention-deficit/hyperactivity disorder in children.

Eiland LS, Bell EA, Erramouspe J. Eiland LS, et al. Ann Pharmacother. 2014 Oct;48(10):1350-5. doi: 10.1177/1060028014541791. Epub 2014 Jun 30. Ann Pharmacother. 2014. PMID: 24982313 Review.

5

Transition from methylphenidate or amphetamine to atomoxetine in children and adolescents with attention-deficit/hyperactivity disorder--a preliminary tolerability and efficacy study.

Quintana H, Cherlin EA, Duesenberg DA, Bangs ME, Ramsey JL, Feldman PD, Allen AJ, Kelsey DK. Quintana H, et al. Clin Ther. 2007 Jun;29(6):1168-77. doi: 10.1016/j.clinthera.2007.06.017. Clin Ther. 2007. PMID: 17692731 Clinical Trial.

6

Dexmethylphenidate extended-release capsules for attention deficit hyperactivity disorder.

McGough JJ, Pataki CS, Suddath R. McGough JJ, et al. Expert Rev Neurother. 2005 Jul;5(4):437-41. doi: 10.1586/14737175.5.4.437. Expert Rev Neurother. 2005. PMID: 16026226 Review.

7

Physician perceptions of the use of medications for attention deficit hyperactivity disorder.

Stockl KM, Hughes TE, Jarrar MA, Secnik K, Perwien AR. Stockl KM, et al. J Manag Care Pharm. 2003 Sep-Oct;9(5):416-23. doi: 10.18553/jmcp.2003.9.5.416. J Manag Care Pharm. 2003. PMID: 14613439 Free PMC article.

8

Adverse Drug Reactions Related to Mood and Emotion in Pediatric Patients Treated for Attention Deficit/Hyperactivity Disorder: A Comparative Analysis of the US Food and Drug Administration Adverse Event Reporting System Database.

Pozzi M, Carnovale C, Mazhar F, Peeters GGAM, Gentili M, Nobile M, Radice S, Clementi E. Pozzi M, et al. J Clin Psychopharmacol. 2019 Jul/Aug;39(4):386-392. doi: 10.1097/JCP.0000000000001058. J Clin Psychopharmacol. 2019. PMID: 31205193

9

Cessation of attention deficit hyperactivity disorder drugs in the young (CADDY)--a pharmacoepidemiological and qualitative study.

Wong IC, Asherson P, Bilbow A, Clifford S, Coghill D, DeSoysa R, Hollis C, McCarthy S, Murray M, Planner C, Potts L, Sayal K, Taylor E. Wong IC, et al. Health Technol Assess. 2009 Oct;13(50):iii-iv, ix-xi, 1-120. doi: 10.3310/hta13490. Health Technol Assess. 2009. PMID: 19883527 Free article.

10

Safety of Methylphenidate and Atomoxetine in Children with Attention-Deficit/Hyperactivity Disorder (ADHD): Data from the Italian National ADHD Registry.

Cortese S, Panei P, Arcieri R, Germinario EA, Capuano A, Margari L, Chiarotti F, Curatolo P. Cortese S, et al. CNS Drugs. 2015;29(10):865-77. doi: 10.1007/s40263-015-0266-7. CNS Drugs. 2015. PMID: 26293742 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

85 results

Results by year